These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16010649

  • 1. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
    Vamvakas EC.
    Transfus Med Rev; 2005 Jul; 19(3):181-99. PubMed ID: 16010649
    [Abstract] [Full Text] [Related]

  • 2. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF.
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [Abstract] [Full Text] [Related]

  • 3. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B.
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [Abstract] [Full Text] [Related]

  • 4. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S, Gowland P, Eyer C, Widmer N, Abonnenc M, Prudent M, Masouridi-Levrat S, Duchosal MA, Niederhauser C.
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [Abstract] [Full Text] [Related]

  • 5. Prevention of transfusion-transmitted cytomegalovirus infection.
    Pamphilon DH, Rider JR, Barbara JA, Williamson LM.
    Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
    [Abstract] [Full Text] [Related]

  • 6. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB, Lichtiger B.
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [Abstract] [Full Text] [Related]

  • 7. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
    Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W.
    Blood; 1995 Nov 01; 86(9):3598-603. PubMed ID: 7579469
    [Abstract] [Full Text] [Related]

  • 8. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center.
    Preiksaitis JK, Sandhu J, Strautman M.
    Transfusion; 2002 Apr 01; 42(4):396-402. PubMed ID: 12076284
    [Abstract] [Full Text] [Related]

  • 9. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ, McCullough J, Balfour HH, Haake RJ, Ramsay NK, Goldman A, Bowman R, Kersey J.
    Bone Marrow Transplant; 1991 Mar 01; 7(3):227-34. PubMed ID: 1647829
    [Abstract] [Full Text] [Related]

  • 10. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
    Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, Murphy M, Chaganti S.
    Transfus Med; 2015 Dec 01; 25(6):418-23. PubMed ID: 26114211
    [Abstract] [Full Text] [Related]

  • 11. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van der Meer JW, Kunst VA.
    Transplantation; 1990 Dec 01; 50(6):964-8. PubMed ID: 2175059
    [Abstract] [Full Text] [Related]

  • 12. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study.
    Preiksaitis JK, Desai S, Vaudry W, Roberts S, Akabutu J, Grundy P, Wilson B, Boshkov L, Hannon J, Joffres M.
    Transfusion; 1997 Sep 01; 37(9):941-6. PubMed ID: 9308642
    [Abstract] [Full Text] [Related]

  • 13. [Leukocyte depletion and infection by cytomegalovirus].
    Mazeron MC.
    Transfus Clin Biol; 2000 Jun 01; 7 Suppl 1():31s-35s. PubMed ID: 10919221
    [Abstract] [Full Text] [Related]

  • 14. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
    Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD.
    Blood; 1991 Jul 01; 78(1):246-50. PubMed ID: 1648976
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.
    Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H.
    Transfusion; 2007 Nov 01; 47(11):1972-83. PubMed ID: 17958525
    [Abstract] [Full Text] [Related]

  • 16. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis.
    Mainou M, Alahdab F, Tobian AA, Asi N, Mohammed K, Murad MH, Grossman BJ.
    Transfusion; 2016 Jun 01; 56(6 Pt 2):1569-80. PubMed ID: 26826015
    [Abstract] [Full Text] [Related]

  • 17. Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.
    Morton S, Peniket A, Malladi R, Murphy MF.
    Transfus Med; 2017 Dec 01; 27(6):444-450. PubMed ID: 28913908
    [Abstract] [Full Text] [Related]

  • 18. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
    Smith D, Lu Q, Yuan S, Goldfinger D, Fernando LP, Ziman A.
    Vox Sang; 2010 Jan 01; 98(1):29-36. PubMed ID: 19695013
    [Abstract] [Full Text] [Related]

  • 19. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
    Nichols WG, Price TH, Gooley T, Corey L, Boeckh M.
    Blood; 2003 May 15; 101(10):4195-200. PubMed ID: 12531791
    [Abstract] [Full Text] [Related]

  • 20. Transfusion-associated cytomegalovirus infections.
    Adler SP.
    Rev Infect Dis; 1983 May 15; 5(6):977-93. PubMed ID: 6318291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.